Risk Factors for Rescue Therapy in Crohn's Patients on Combination Therapy After Discontinuation of the Immunomodulator

被引：0
|
作者：
Fischer, Monika
Campbell, Sarah C.
Johnson, Cynthia S.
Helper, Debra J.
Chiorean, Michael V.
机构：
来源：
GASTROENTEROLOGY | 2014年 / 146卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1373
引用
收藏
页码：S450 / S450
页数：1
相关论文
共 50 条
  • [1] Need for rescue therapy in IBD patients on infliximab maintenance therapy after discontinuation of immunomodulator
    Fischer, M.
    Helper, D.
    Chiorean, M.
    Juliar, B.
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S1 - S2
  • [2] Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up
    Fischer, Monika
    Campbell, Sarah C.
    Calley, Cynthia S. J.
    Helper, Debra J.
    Chiorean, Michael V.
    Fadda, Hala M.
    DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (11) : 3131 - 3137
  • [3] Risk Factors for Rescue Therapy in Crohn’s Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up
    Monika Fischer
    Sarah C. Campbell
    Cynthia S. J. Calley
    Debra J. Helper
    Michael V. Chiorean
    Hala M. Fadda
    Digestive Diseases and Sciences, 2017, 62 : 3131 - 3137
  • [4] Discontinuation of Infliximab Therapy in patients with Crohn's disease: outcome and risk factors
    Chen, Zhao
    Xiang, Cheng
    Hu, Huiqin
    Jiang, Bo
    Qiu, Chen
    Wang, Guozhen
    Wang, Xinying
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 154 - 154
  • [5] Discontinuation of infliximab in patients with Crohn's disease on combination therapy
    Hindson, Jordan
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (03) : 131 - 131
  • [6] Discontinuation of infliximab in patients with Crohn’s disease on combination therapy
    Jordan Hindson
    Nature Reviews Gastroenterology & Hepatology, 2023, 20 : 131 - 131
  • [7] Risk of relapse in ulcerative colitis patients in clinical remission with combination therapy (anti-TNF and azathioprine) after immunomodulator discontinuation
    Mihai, C.
    Dranga, M.
    Gavrilescu, O.
    Ungureanu, I.
    Didita, A.
    Chiosa, A. M.
    Savin, A.
    Popa, I.
    Popa, R.
    Jigaranu, O.
    Cijevschi-Prelipcean, C.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S275 - S275
  • [8] Addition of an Immunomodulator as a Rescue Therapy for Loss of Response to Adalimumab Dose Escalation in Patients With Crohn's Disease
    Papamichael, Konstantinos
    Karatzas, Pantelis
    Mantzaris, Gerassimos J.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 (07): : 589 - 590
  • [9] Predictive factors associated with the need to escalate to biological therapy in patients commencing immunomodulator therapy for Crohn's disease
    Con, D.
    Vasudevan, A.
    Parthasarathy, N.
    Bishara, M.
    Luber, R.
    Joshi, N.
    Wan, A.
    Rickard, J.
    Sparrow, M.
    Gibson, P.
    Van Langenberg, D.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 148 - 148
  • [10] COMBINATION THERAPY WITH VEDOLIZUMAB AND AN IMMUNOMODULATOR IS PREDICTIVE OF IMPROVED PERIANAL FISTULA CLOSURE IN PATIENTS WITH CROHN'S DISEASE
    Gold, Stephanie
    Cohen-Mekelburg, Shirley A.
    Schneider, Yecheskel
    Bosworth, Brian P.
    Steinlauf, Adam F.
    Scherl, Ellen
    GASTROENTEROLOGY, 2018, 154 (06) : S834 - S835
12345